The dog as an animal model for bladder and urethral urothelial carcinoma: comparative epidemiology and histology by de Brot, Simone et al.
ONCOLOGY LETTERS  
Abstract. Despite the recent approval of several novel agents 
for patients with metastatic urothelial carcinoma (UC), survival 
in this setting remains poor. As such, continued investigation 
into novel therapeutic options remains warranted. Pre‑clinical 
development of novel treatments requires an animal model 
that accurately simulates the disease in humans. The aim of 
the present study was to evaluate the dog as an animal model 
for human UC. A total of 260 cases of spontaneous, untreated 
canine primary urethral and urinary bladder UC, were epide‑
miologically and histologically assessed and classified based 
on the current 2016 World Health Organization (WHO) tumor 
classification system. Canine data was compared with human 
data available from scientific literature. The mean age of dogs 
diagnosed with UC was 10.22 years (range, 4‑15 years), which 
is equivalent to 60‑70 human years. The results revealed a 
high association between UC diagnosis with the female sex 
[odds ratio (OR) 3.51; 95% confidence interval (CI) 2.57‑4.79; 
P<0.001], surgical neutering (OR 4.57; 95% CI 1.87‑11.12; 
P<0.001) and breed (OR 15.11 for Scottish terriers; 95% CI 
8.99‑25.41; P<0.001). Based on the 2016 WHO tumor (T), 
node and metastasis staging system, the primary tumors 
were characterized as T1 (38%), T2a (28%), T2b (13%) and 
T3 (22%). Non‑papillary, flat subgross tumor growth was 
strongly associated with muscle invasion (OR 31.00; P<0.001). 
Irrespective of subgross growth pattern, all assessable tumors 
were invading beyond the basement membrane compatible 
with infiltrating UC. Conventional, not further classifiable 
infiltrating UC was the most common type of tumor (90%), 
followed by UC with divergent, squamous and/or glandular 
differentiation (6%). Seven out of the 260 (2.8%) cases 
were classified as non‑urothelial based on their histological 
morphology. These cases included 5 (2%) squamous cell carci‑
nomas, 1 (0.4%) adenocarcinoma and 1 (0.4%) neuroendocrine 
tumor. The 2 most striking common features of canine and 
human UC included high sex predilection and histological 
tumor appearance. The results support the suitability of the 
dog as an animal model for UC and confirm that dogs also 
spontaneously develop rare UC subtypes and bladder tumors, 
including plasmacytoid UC and neuroendocrine tumor, which 
are herein described for the first time in a non‑experimental 
animal species.
Introduction
Bladder cancer (BC) is the ninth most common malignancy 
worldwide and the most common cancer involving the urinary 
system. BC comprises approximately 2% of all cancers, with 
about 330,000 new BC cases each year globally (1,2). The 
highest incidence rates are observed in highly developed 
countries, where BC is the fourth and 14th most common 
cancer in men and women, respectively (2). Despite ongoing 
effort to improve therapeutic options, there is still no cura‑
tive therapy available for metastatic disease. The pre‑clinical 
development of new treatments requires an animal model that 
accurately simulates the disease in people. Rodent animal 
models with experimentally induced bladder cancer have 
been shown to be valuable, but their translational relevance 
has been limited (3‑5). Therefore, well characterized sponta‑
neous bladder cancers in companion animals could represent 
a useful tool to advance the development of improved diag‑
nostics and therapeutics. Indeed dogs develop spontaneous 
BC, more specifically urothelial carcinoma (transitional cell 
carcinoma), with striking clinical, histopathological and 
molecular similarities compared to humans (6). Furthermore, 
companion animals and their owners share the environment, 
including exposure to carcinogenic components. In addi‑
tion, other advantages of using spontaneous urinary bladder 
cancer in pet dogs as an animal model for human UC are: i) 
reduced use of research animals, ii) the shorter lifespan of 
dogs, relative to people, makes time‑efficient clinical studies 
possible and iii) dogs show a similar response to therapy used 
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to treat people (7‑11). Yet one limitation to the use of the dog 
in preclinical studies of BC has been access to robust clinical 
and pathologic datasets. For this reason, the present study, 
which is one of the largest yet undertaken comparative studies, 
aims to evaluate the dog as animal model for human urothelial 
carcinoma by comparing the epidemiology and histology of 
n=260 canine urinary bladder and urethral urothelial carci‑
noma to the data available in literature regarding their human 
counterpart.
Materials and methods
The present study was reviewed and approved by the University 
of Nottingham's ethical review committee. Informed written 
consent was obtained from the dog owners upon sample 
submission. All patient data has been anonymized. The 
present retrospective study includes archived formalin‑fixed 
paraffin‑embedded (FFPE) tissues from 260 dogs with primary 
urethral (n=61) or urinary bladder (n=199) carcinomas. All 
samples were taken from pet dogs living in the United Kingdom 
(UK) and were originally submitted for diagnostic purposes. 
Two hundred fifty‑nine cases were provided by a private diag‑
nostic pathology laboratory (Bridge Pathology Ltd., Bristol, 
UK) which received the tissue samples between October 2008 
and April 2015. One additional case of canine urinary bladder 
carcinoma which was submitted to the University Nottingham 
Veterinary Pathology Service in May 2016 was also included. 
Non‑invasive urothelial lesions, including papillomas, were 
excluded from the study due to the low number of cases in the 
present dog population. Tissue of canine in situ UC was not 
available. From the originally retrieved n=265 cases of UC, two 
cases were excluded due to poor tissue section quality, another 
two cases due to lack of convincing neoplastic features, and 
one case due to lack of information about dog breed and age. 
The following case information was available: Age at the time 
of first tumor diagnosis, sex, neutering status, and dog breed. 
All canine cases (n=93,862) submitted to the same laboratory 
within the same time period were used as control population. 
These control dogs were diagnosed with a wide range of 
neoplastic and non‑neoplastic diseases in various organs and 
tissues, excluding carcinoma of the lower urinary tract. 
Haematoxylin and eosin stained tissue sections of all 260 cases 
were available which were digitalized (scanner 3DHISTECH 
Pannoramic 250 Flash III) and assessed using the software 
3DHISTECH Case Viewer by a board‑certified veterinary 
pathologist (SdB), with support of a certified human uropatholo‑
gist (BR) and a second veterinary pathologist (LGR). All cases 
were histologically assessed for tumor stage and histological 
subtype, based on the World Health Organization (WHO) 
tumor classification system 2016 (12). Subgross tumor growth 
patterns were evaluated histologically at a low magnification 
(1 and 2x). Epidemiological and pathological canine data was 
compared with data available from scientific human literature 
which was available on PubMed (https://www.ncbi.nlm.nih.
gov/pubmed/) in April 2017. Cancer incidence was calculated 
in percentage (%) for each dog breed (n=60 different breeds). 
100% cancer incidence was defined as the total number of 
dogs of the same breed in the control population. Breeds with 
incidence rates above average (>0.823%) and with a minimum 
of n=5 cancer cases were defined as risk breeds. Three different 
breeds (Scottish terrier, Shetland sheepdog and West Highland 
White terrier) fulfilled these criteria and were grouped together 
as ‘risk breeds’. ‘Non‑risk dog breeds’ were defined as all dog 
breeds, including cross breeds, excluding Scottish terriers, 
Shetland Sheepdogs, and West Highland White terriers. Odds 
ratios were calculated in order to quantify the risk of dog breed, 
sex, neutering status with the development of cancer, and in 
order to quantify the risk of non‑papillary tumor growth with 
muscle‑invasive tumor growth. An independent t‑test was 
performed to compare the mean age of risk breeds vs. non‑risk 
breeds, of dogs with muscle‑invasive vs. non muscle‑invasive 
tumor growth, and of dogs with papillary vs. non‑papillary 
tumor growth, respectively. Chi‑square test was used to test 
for associations between tumor incidence and dog breed, sex, 
and neutering status, and to analyze the association of tumor 
invasive growth with tumor growth pattern, dog breed, and sex. 
Binary logistic regression analysis was performed in order to 
identify and weigh risk factors, including dog breed, sex, and 
neutering. P<0.05 was considered to indicate a statistically 
significant difference. Statistical analyses were performed 
using SPSS v.22.0 (IBM Corp., Armonk, NY, USA).
Results
A total of 260 dogs with spontaneous urinary bladder (199/260, 
77%) and primary urethral (61/260, 23%) urothelial carcinoma 
(UC) were included in this study. Tables I and II summarize 
the main canine epidemiological findings and compare them 
with the corresponding human data available in the literature.
The mean age of dogs diagnosed with UC was older 
compared to dogs without UC (10.21 [+/‑2.0, range 4‑15] years 
vs. 7.1 [+/‑3.6] (mean +/‑SD, P<0.001). Dog breeds with only 
1 case of UC were excluded from any further analysis (leaving 
66,317 cases; 222 (0.3%) with UC). In univariate analyses 
[odds ratio (95% confidence interval), P<0.001], female sex 
[OR, 3.51 (2.57‑4.79)], neutering [OR, 4.57 (1.87‑11.12)] and 
breed (OR 15.11 [8.97‑25.41] for Scottish terriers, OR 6.82 
[3.01‑15.49] for Shetland sheepdogs, and OR 2.79 [1.80‑4.35] 
for West Highland white terriers) were identified as signifi‑
cant predictors of UC (Table I). All remained significant 
(P<0.001) in multivariate analyses (Table I). In addition, 
when the three top risk breed dogs were grouped together, 
they were found to be diagnosed with UC at a significantly 
younger age [mean 112.14 months (9.35 years), SD 19.16] 
compared to the group containing ‘non‑risk dog breeds’ [mean 
124.69 months (10.39 years), SD 24.74] (P<0.001). This effect 
was most evident for female neutered Scottish terriers (Fig. 1). 
‘Non‑risk dog breeds’ were defined as all dog breeds, including 
cross breeds, excluding Scottish terriers, Shetland Sheepdogs, 
and West Highland White terriers.
All cases were histologically assessed for tumor stage and 
histological subtype, based on the World Health Organization 
(WHO) tumor classification system 2016 (12,13). Tumor loca‑
tion, growth pattern and main histological features of the 
studied dogs are summarized in Table III together with the 
equivalent information extracted from the human literature.
Gross tumor location was available for 29/199 (15%) 
bladder and 10/61 (16%) urethral UC cases. The most 
common location within the bladder was the neck (14/29, 
48%), followed by the trigone (9/29, 28%), cranial (3/29 10%), 
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ventral (1/29, 4%) and dorsal (1/29, 4%) bladder. In 2/29 cases 
(7%), tumor growth was present in both bladder neck and 
cranial areas. The location of urethral UC was more common 
in the distal (8/10, 80%) than in the proximal (2/10, 20%) 
urethra.
The subgross tumor growth pattern could be assessed 
in 66/199 (33%) bladder UC cases, which were provided 
as full transmural tissue sections. Two different types of 
subgross growth appearance were recognized, papillary and 
non‑papillary (also referred to as flat). Papillary UC (Fig. 2A) 
were equally as common (33/66, 50%) as flat (Fig. 2B) (33/66, 
50%) tumors, with identical female: Male ratio of 1: 1.57 in 
both growth patterns (21/33, 67% females, 12/33, 33% males). 
Irrespective of growth pattern, all UC were invading beyhond 
the basement membrane, compatible with infiltrating UC 
based on the WHO 2016 tumor classification.
When applying the tumor, node and metastasis (TNM) 
staging system provided by the 2016 WHO classifica‑
tion system (12), tumor characterization was limited to 
the assessment of the primary tumor. Information about 
the involvement of lymph nodes and presence of distant 
metastatic spread was not available, which prevented the 
performance of an overall tumor staging. The extent of tumor 
infiltration into the bladder wall could be assessed in 64/199 
(32%) bladder UC cases which were available as transmural 
tissue sections. Thirty‑eight % (24/64) of cases were limited 
to the lamina propria mucosae (T1), 28% (18/64) invaded 
the superficial muscularis propria (T2a), and 13% (8/64) 
the deep muscularis propria (T2b). A substantial number 
(14/64, 22%) of UC cases invaded perivesicular tissue (T3). 
Muscle‑invasive growth could be assessed in 76/199 (38%) 
Table I. Risk factors for urothelial carcinoma in the studied dog population. 
 Absolute Prevalence Univariate   Multivariate
Variables nos.  (%) OR 95% CI P‑value OR 95% CI P‑value
Female sex   3.51 2.57‑4.79 <0.001 2.92 2.17‑3.91 <0.001
  With UC 170 77      
  Without UC 31,243 48      
Neutering   4.57 1.87‑11.12 <0.001 3.75 1.85‑7.60 <0.001
  With UC 166 75      
  Without UC 37,054 88a      
Breed        
  Scottish terrier   15.11 8.99‑25.41 <0.001 19.51 11.48‑33.16 <0.001
    With UC 16 7      
    Without UC 338 0.5      
  Shetland sheepdog   6.82 3.01‑15.49 <0.001 12.33 5.35‑28.40 <0.001
    With UC 6 3      
    Without UC 268 0.4      
  West Highland   2.79 1.80‑4.35 <0.001 3.30 2.03‑5.36 <0.001
  white terrier
    With UC 22 10      
    Without UC 2,504 4      
Female sex, neutering and certain dog breeds were identified as risk factors by univariate and multivariate regression analysis. aNote that 
neutering status was unknown in 23,997 (36%) of cases. CI, Confidence interval; OR, odds ratio; UC, urothelial carcinoma.
Figure 1. Effect of sex, neutering, age and dog breed on cancer incidence. The 
risk of UC in Scottish terriers increased with age. This effect was the greatest 
in female neutered dogs. Non‑risk breeds were defined as all dog breeds 
including cross breeds, excluding Scottish terriers, Shetland sheepdogs and 
West Highland White terriers. Data are presented as the mean ± the standard 
error of the mean. UC, urothelial carcinoma.
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bladder UC cases. More than two thirds (52/76, 68%) were 
muscle‑invasive tumors, which is compatible with high 
tumor stage. The tumor growth pattern of muscle‑invasive 
UC could be assessed in 41/52 (79%) cases, and it was more 
commonly flat (30/41, 73%) than papillary (11/41, 27%). 
This was in contrasts to the non‑muscle‑invasive UC, the 
vast majority of which (22/24, 92%) presented with a papil‑
lary growth, with only rare flat tumor growth (2/24, 8%). 
Non‑papillary, flat tumor growth was statistically signifi‑
cantly strongly associated with tumor muscle invasion (OR 
31.00, 95% CI 66.24‑153.95).
Conventional, not further classifiable infiltrating UC was 
the most common type of tumor (234/260, 90%), followed 
by UC with divergent differentiation (15/260, 6%) (squamous 
[8/260, 3%), glandular (5/260, 2%) or both (2/260, 1%)], and 
squamous cell carcinoma (5/260, 2%). One case was identi‑
fied to be a bladder adenocarcinoma (not otherwise specified). 
Two rare urinary tract tumors, including primary urethral 
plasmacytoid UC and neuroendocrine bladder tumor, have 
been identified in one dog each (Fig. 3). Eight of the 234 
not further classifiable infiltrating UC cases presented with 
certain characteristic histological features within a low 
percentage (1 to 20%) of the studied tissue section, including 
micropapillary and microcystic growth (Fig. 4), neuroen‑
docrine differentiation as well as the presence of neoplastic 
cells with plasmacytoid, rhabdoid, signet‑ring cell, lipid‑rich 
or glycogen‑rich appearance (Fig. 5). Since the divergent 
differentiation was however only observed in a minor portion 
of the examined tumor tissue, these tumors were diagnosed 
as not further classifiable infiltrating UC and not as UC with 
divergent differentiation. The urethral plasmacytoid UC was 
found in a 9‑year‑old male neutered crossbreed dog with a 
history of dyschezia and prostate enlargement. The submitted 
and histologically examined tissue was limited to urethra. 
Prostate tissue was not available and no further information 
about the follow‑up of this dog was given. The neuroendo‑
crine bladder tumour was diagnosed in a 13‑year‑old female 
neutered 7 kg crossbreed dog with reported weight loss 
since a few months and a history of polyuria and polydipsia, 
pollakisuria, haematuria, and increasing lethargy over a 
period of less than 2 months. The tumor was diagnosed based 
on cystoscopy and biopsy. Due to late tumor diagnosis with 
very advanced disease and poor prognosis, the dog's owner 
decided against surgery and chemotherapy and elected eutha‑
nasia 3 weeks after the tumor diagnosis was made. Consent 
for a full post‑mortem examination was given and confirmed 
the primary bladder tumor with metastases in lung, medial 
iliac and sacral lymph nodes.
Figure 5. Microphotographs of urothelial carcinoma with different cellular 
features in the urinary bladder of four dogs visualised using H&E staining. 
(A) Rhabdoid features in a 9‑year‑old female Labrador retriever. (B) Presence 
of signet ring cells in a 12‑year‑old female neutered Labrador retriever. 
(C) Glycogen rich areas in a 10‑year‑old male Jack Russell terrier. (D) Lipid 
rich areas in a 9‑year‑old female neutered West Highland White terrier. 
Magnification, (A) x300 and (B‑D) x200. H&E, haematoxylin and eosin.
Figure 4. Microphotographs of urothelial carcinoma with different histolog‑
ical growth patterns in the urinary bladder of two dogs visualised using H&E 
staining. (A) Micropapillary growth in a 10‑year‑old female neutered lurcher. 
(B) Microcystic growth in a 12‑year‑old male neutered miniature pinscher. 
Magnification, (A) x100 and (B) x50. H&E, haematoxylin and eosin.
Figure 3. Microphotographs of two rare tumor variants in two dogs visualised 
using H&E staining. (A) Primary urethral plasmacytoid urothelial carcinoma 
in a 9‑year‑old male neutered crossbreed dog. Round anaplastic cells grew in a 
sheet‑like discohesive pattern. (B) Neuroendocrine carcinoma in the urinary 
bladder of a 13‑year‑old female neutered crossbreed dog. Highly anaplastic 
cells formed small cell nests and trabecules. Magnification, (A) x300 and 
(B) x100. H&E, haematoxylin and eosin.
Figure 2. Microphotographs of urothelial carcinoma in the urinary bladder 
of two dogs with H&E staining. Tumour growth was (A) papillary in a 
6‑year‑old female entire giant schnauzer and (B) flat in an 11‑year‑old male 
neutered Cavalier King Charles spaniel, respectively. Magnification, (A) x3 
and (B) x4. H&E, haematoxylin and eosin.
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Finally, non‑conventional UC was associated with 
muscle‑invasive tumor growth (P<0.001), being compatible 
with higher tumor stage.
Discussion
The present study confirms the previously observed striking 
epidemiological and pathological similarities between 
canine and human UC (6,14). The number of comparative 
human and canine bladder cancer studies available in the 
literature is still very low, with the most relevant studies 
being done in North America (15‑20). The present study 
is the largest study with comparative epidemiology and 
histology, which includes 260 cases. It demonstrates that 
similar to the situation in people, canine UC mainly affects 
elderly patients. The mean age of dogs diagnosed with UC 
was over 10 years, which is equivalent to approximately 
60 to 70 human years (21), compatible with the mean age 
of people diagnosed with UC. Both canine and human UC 
have a strong sex predilection. While men are at a three‑fold 
higher risk to develop UC compared to women, the situa‑
tion is exactly the opposite in dogs. Similar to the situation 
in people, the reason for the sex predisposition is unknown 
in dogs. Behavioral, anatomic, physiological and hormonal 
gender differences have been discussed, but remain specula‑
tive (22,23). It is important to take into account that most 
of the dogs in the present study were surgically castrated 
which could potentially have contributed to the observed 
female predisposition for developing UC. Indeed, neutering 
appeared as a risk factor for UC for both female and male 
dogs in the present and previous studies (6). Interestingly, a 
similar phenomenon can be seen in women with a history of 
bilateral oophorectomy, who have a higher risk to develop 
UC (22,23). Given that castration causes a change in the level 
of sex hormones and their receptors, these proteins likely play 
a major role in the carcinogenesis of UC. Previous studies 
have shown that reduced androgen receptor and increased 
estrogen receptor‑beta expression are associated with higher 
tumor stage and grade, respectively (24‑28).
Another remarkable feature of canine UC is its high 
predisposition for certain dog breeds (14,17), which we could 
confirm in our study. Dogs of the same breed are genetically 
closely related and can be compared to related human fami‑
lies. The Scottish terrier has been previously shown to be the 
breed with the highest risk (up to over 20‑fold) to develop 
UC (14,17). Present results confirm this observation, which 
raises high suspicion of a strong genetic component of UC in 
certain dog breeds. Interestingly, the three dog breeds with 
highest risk to develop UC were significantly younger at the 
time of tumor diagnosis, compared to other dog breeds. The 
age difference was just over one year, which would be equiva‑
lent to approximately 7 human years (21).
Pathologically, canine and human UC are very similar, 
both grossly and histologically. UC affects most commonly 
the urinary bladder in both people and dogs and represents 
the most common (over 90%) type of bladder cancer in both 
species. The lateral and posterior wall are the most common 
sites of UC in people (29‑31), whereas dogs in our and 
previous studies tend to have UC within the neck and trigone 
area (6,32). Reasons for the difference in preferred bladder 
subsites of UC between men and dogs are not known, but they 
may be due to the different orientation of the bladder within 
the body, leading to different intravesical urine flow. The 
prognostic significance of the different tumor bladder subsites 
is reported with some conflicting results, but involvement of 
neck or trigone appears to be associated with higher tumor 
stage and worse prognosis in people (29,31). This could poten‑
tially explain the higher UC tumor stages in dogs compared 
to men.
The vast majority, between 80 and 90%, of human UC 
grow papillary (30). Non‑papillary (flat or endophytic) growth 
is much less common in people. This is in contrast to the find‑
ings of the here studied canine tumors which presented with 
an equal number of papillary and flat tumors. Interestingly, 
non‑papillary growth has been demonstrated to be associated 
with higher tumor grade, muscle invasion and poor prognosis 
in people (30,33). The studied canine data confirms this 
observation.
Histologically, the present study demonstrates that UC of 
people and dogs are strikingly similar and directly compa‑
rable. Non‑conventional UC are less common in both species 
and most frequently comprise UC with divergent, glandular 
and/or squamous, differentiation. Other UC subtypes are 
rare in both species, but important to recognize given their 
association with poor prognosis (34). In the studied canine 
population, one case of primary urethral plasmacytoid UC in 
a male neutered dog, and one case of neuroendocrine tumor 
in the bladder of a female neutered dog were identified. 
Both tumors were high grade with evidence of intravascular 
neoplastic growth in the plasmacytoid UC and widespread 
lymph node and distant metastases in the neuroendocrine 
tumor, respectively. Neither of these two tumor types have 
been described in any non‑experimental animal species and 
are herein reported for the first time as spontaneous tumors 
in an animal species. Other histological features, including 
micropapillary and microcystic growth, and rhabdoid, 
signet‑ring cell, lipid‑rich and glycogen‑rich appearance of 
neoplastic cells were observed in a small proportion of the 
herein studied canine cases. These histological tumor features 
are poorly described in animals, but are well known features 
of UC in people (13,34,35). These results therefore further 
support the value and suitability of the dog as animal model 
for UC in people.
In conclusion, canine and human UC are epidemio‑
logically and pathologically directly comparable, which 
promotes the dog as a valuable animal model. Canine 
UC has an extraordinarily high predisposition for certain 
genetically closely related dog breeds which suggests a 
strong genetic component which needs further investiga‑
tion. Female surgically neutered dogs are at highest risk to 
develop UC which leads to the speculation that sex hormones 
are crucial in the carcinogenesis of UC. Given the typically 
high tumor grades in dogs, canine UC appears to mimic the 
malignant muscle‑invasive form of UC in people which is 
known to lack a well‑established animal model that is so 
urgently needed to discover new therapeutic options. Finally, 
rare urinary tract tumors, including plasmacytoid UC and 
neuroendocrine tumor, occur spontaneously in dogs and are 
herein described for the first time in a non‑experimental 
animal species.
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